Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.
Full description
PRIMARY OBJECTIVE:
I. To evaluate immune profile of AML patients receiving venetoclax plus azacitidine induction chemotherapy.
SECONDARY OBJECTIVE:
I. To determine clinical responses based on immune infiltrated vs immune depleted subtypes of AML receiving azacitidine and venetoclax chemotherapy.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and bone marrow aspirate on study. Patients' medical records are reviewed.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Adults > 18 yrs of age with diagnosis of acute myeloid leukemia who received azacitidine plus venetoclax chemotherapy
- Treatment naive adult acute myeloid leukemia patients
Exclusion criteria
- Acute myeloid leukemia patients receiving azacitidine and venetoclax as salvage therapy will be excluded
- Patients who are pregnant or breast-feeding
Trial design
80 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal